The impact of metabolic syndrome on left ventricular myocardial performance

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 2, 2010, Pages 121-127

  Voulgari, Christina ^a   Moyssakis, Ioannis ^b   Papazafiropoulou, Athanasia ^a   Perrea, Despoina ^a   Kyriaki, Despoina ^a   Katsilambros, Nicholas ^a   Tentolouris, Nicholas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Heart failure; Insulin resistance; Low grade inflammation; Metabolic syndrome; Microalbuminuria; Myocardial performance; Tei index

Indexed keywords

ADULT; ARTICLE; BODY MASS; FEMALE; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; TEI INDEX;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; VENTRICULAR FUNCTION, LEFT; WAIST CIRCUMFERENCE;

EID: 77950447086     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1063     Document Type: Article

References (44)

1. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
2. Reaven GM. Banding lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
3. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
4. Chinali M, Devereux RB, Howard BV, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004; 93: 40-44.
5. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003; 107: 448-454.
6. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 2007; 101: 759-767.
7. Hayden MR, Chowdhury N, Govindarajan G, Karuparthi PR, Habibi J, Sowers JR. Myocardial myocyte remodeling and fibrosis in the cardiometabolic syndrome. J Cardiometab Syndr 2006; 1: 326-333.
8. Hammer S, van der Meer RW, Lamb HJ, et al. Progressive caloric restriction induces dose dependent changes in myocardial triglyceride content and diastolic function in healthy men. J Clin Endocrinol Metab 2008; 93: 497-503.
9. Turhan H, Yasar AS, Yagmur J, Kurtoglu E, Yetkin E. The impact of metabolic syndrome on left ventricular function: evaluated by using the index of myocardial performance. Int J Cardiol 2009; 132: 382-386.
10. Dwyer EM, Asif M, Ippolito T, Gillespie M. Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries. Am Heart J 2000; 139: 297-304.
11. Bella JN, Devereux RB, Roman MJ, et al. Separate and joint effects of systemic hypertension and diabetes mellitus on left ventricular structure and function in American Indians (the Strong Heart Study). Am J Cardiol 2001; 87: 1260-1265.
12. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
13. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167: 1930-1936.
14. Tousoulis D, Charakida M, Stefanadi E, Siasos G, Latsios G, Stefanadis C. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007; 115: 144-150.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): 1-266.
17. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: A simple and reproducible measure of cardiac function - a study in normal and dilated cardiomyopathy. J Cardiol 1995; 26: 357-366.
18. Tei C, Nishimura RA, Seward JB, Tajik AJ. Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements. J Am Soc Echocardiogr 1997; 10: 169-178.
19. Haney MF, A'Roch R, Johansson G, Poelaert J, Biber B. Beat-to-beat change in "myocardial performance index" related to load. Acta Anaesthesiol Scand 2007; 51: 545-552.
20. Cannesson M, Jacques D, Pinsky MR, Gorcsan J III. Effects of modulation of left ventricular contractile state and loading conditions on tissue Doppler myocardial performance index. Am J Physiol Heart Circ Physiol 2006; 290: H1952-H1959.
21. Cheung MM, Smallhorn JF, Redington AN, Vogel M. The effects of changes in loading conditions and modulation of inotropic state on the myocardial performance index: comparison with conductance catheter measurements. Eur Heart J 2004; 25: 2238-2242.
22. Gillebert TC, Van de Veire N, De Buyzere ML, Sutter JD. Time intervals and global cardiac function. Use and limitations. Eur Heart J 2004; 25: 2185-2286.
23. Moller J, Poulsen S, Egstrup K. Effect of preload alternations on a new Doppler echocardiographic index of combined systolic and diastolic performance. J Am Soc Echocardiogr 1999; 12: 1065-1072.
24. Palloshi A, Fragasso G, Silipigni C, et al. Early detection by the Tei index of carvedilol-induced improved left ventricular function in patients with heart failure. Am J Cardiol 2004; 94: 1456-1459.
25. Arnlöv J, Lind L, Andrén B, Risérus U, Berglund L, Lithell H. A Doppler-derived index of combined left ventricular systolic and diastolic function is an independent predictor of cardiovascular mortality in elderly men. Am Heart J 2005; 149: 902-1147
26. Bruch C, Schmermund A, Marin D, et al. Tei-index in patients with mild-to-moderate congestive heart failure. Eur Heart J 2000; 21: 1888-1895.
27. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008; 51: 93-102.
28. Williams RS. Apoptosis and heart failure. N Engl J Med 1999; 341: 759-760.
29. Nada T, Fukuda N, Yamaguchi Y, et al. Age-related changes in cardiac performance index (TEI index) with special reference to the difference between the ventricles. J Cardiol 2007; 49: 337-344.
30. Vyssoulis P, Karpanou EA, Michaelidis AP, et al. Microalbuminuria and global myocardial function in patients with essential hypertensive. Int J Cardiol 2008; 126: 268-272.
31. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
32. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
33. Marfella R, Esposito K, Siniscalchi M, Cacciapuoti F, Giugliano F, Labriola D. Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. Diabetes Care 2004; 27: 47-52.
34. Celik T, Iyisoy A, Celik M, Yuksel UC, Kardesoglu E. C-reactive protein in chronic heart failure: A new predictor of survival. Int J Cardiol 2009; 135: 396-397.
35. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005; 28: 690-693.
36. Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation 1997; 95: 778-781.
37. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-998.
38. Kell R, Haunstetter A, Dengler TJ, Zugck C, Kubler W, Haass M. Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. Eur Heart J 2002; 23: 70-78.
39. Nielson C, Lange T. Blood glucose and heart failure in nondiabetic patients. Diabetes Care 2005; 28: 607-611.
40. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'agostino RB, Wilson PWF. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007; 30: 1219-1225.
41. Ingelsson E, Arnlöv J, Lind L, Sundström J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 2006; 92: 1409-1413.
42. Li C, Ford ES, McGuire LC, Mokdad AH. Association of metabolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health 2007; 61: 67-73.
43. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 2008; 168: 207-217.
44. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.